GNMSF (Genmab AS) ROCE %: 6.57% (As of Mar. 2026)


GNMSF Genmab AS GNMSF
95 GF Score
Price $262.00
GF Value $343.48
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS ROCE %?

Genmab AS GNMSF +1.77% 95 ROCE % is 6.57% as of Mar. 2026. GuruFocus rates GNMSF with a GF Score™ of 95/100 and a GF Value™ of $343.48 (Modestly Undervalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Genmab AS's annualized ROCE % for the quarter that ended in Mar. 2026 was 6.57%.

Genmab AS  (OTCPK:GNMSF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Genmab AS ROCE % Related Terms

Genmab AS ROCE % Historical Data

* Premium members only.

The historical data trend for Genmab AS's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS ROCE % Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.61 26.51 18.51 25.52 14.78

Genmab AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.32 29.63 32.03 4.47 6.57
GNMSF
95GF Score
Genmab AS GNMSF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS ROCE % Calculation

Genmab AS's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=1265/( ( (6414 - 744) + (12873 - 1427) )/ 2 )
=1265/( (5670+11446)/ 2 )
=1265/8558
=14.78 %

Genmab AS's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=744/( ( (12873 - 1427) + (12376 - 1178) )/ 2 )
=744/( ( 11446 + 11198 )/ 2 )
=744/11322
=6.57 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 6.57% mean?
Genmab AS (GNMSF) has a ROCE % of 6.57% as of Mar. 2026.
Is Genmab AS's ROCE % too high?
Genmab AS's current ROCE % is 6.57%. Overall, Genmab AS has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's ROCE % compare to VRTX and REGN?
Genmab AS's ROCE % of 6.57% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Genmab AS's current ROCE % is 6.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (GNMSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $343.48, compared to a current price of $262.00 — trading 23.7% below its estimated fair value. The current ROCE % is 6.57%. Genmab AS's overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Genmab AS (GNMSF), the current ROCE % is 6.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (GNMSF) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of $262.00 is trading 23.7% below its estimated GF Value™ of $343.48. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for GNMSF:

  • ROCE %: 6.57%
  • GF Value™: $343.48 vs. price of $262.00 (23.7% below fair value)
  • GF Score™: 95/100 with 5 warning signs

No single metric tells the full story. See the GNMSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
95GF Score

Get the complete analysis for GNMSF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$262.00
Price
$343.48
GF Value